Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Isatuximab Plus RVd Improves MRD Negativity Rates in Transplant-Eligible, Newly Diagnosed Myeloma

December 11th 2021

The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) demonstrated superior minimal residual disease rates vs RVd alone when used as induction treatment in patients with transplant-eligible newly diagnosed multiple myeloma.

Daratumumab Plus Talquetamab Demonstrates Tolerable Safety Profile and High Response Rates in R/R Multiple Myeloma

December 11th 2021

Daratumumab plus talquetamab demonstrated a tolerable safety profile and induced responses in more than 75% of patients with relapsed/refractory multiple myeloma across dose levels.

Daratumumab Combos Showcase Superior Survival in First- Vs Second-Line Settings in Transplant-Ineligible Multiple Myeloma

December 11th 2021

Daratumumab, lenalidomide, and dexamethasone demonstrated an overall survival advantage in the first-line setting compared with the same agents in the second-line setting in patients with transplant-ineligible multiple myeloma.

Ixazomib/Daratumumab Showcases Favorable Safety in Elderly Frail Patients With Relapsed/Refractory Myeloma

December 11th 2021

The combination of daratumumab plus ixazomib, without dexamethasone, was found to have a favorable safety profile in very elderly frail patients with relapsed or refractory multiple myeloma and high cytogenetic risk.

Less-Toxic Ixazomib/Daratumumab Combo Attempted for Intermediate-Fit, Non-Transplant Eligible Newly Diagnosed Multiple Myeloma

December 11th 2021

The combination of ixazomib, daratumumab, and low-dose dexamethasone elicited an objective response rate of 71% in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Multidisciplinary Approach is Key to Managing Belantamab Mafodotin–Associated Keratopathy in Myeloma

December 11th 2021

Sagar Lonial, MD, FACP, discusses strategies for managing belantamab mafodotin–associated keratopathy in patients with multiple myeloma.

ASH 2021 Is Packed With Practice-Changing Hematologic Cancer Data

December 9th 2021

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

Dr. Lonial on the Management of Belantamab Mafodotin–Related Keratopathy in Multiple Myeloma

December 8th 2021

Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.

Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple Myeloma

December 6th 2021

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

Dr. Lee on Treatment Considerations in Smoldering Multiple Myeloma

December 2nd 2021

Sarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.

Secura Bio Withdraws Panobinostat Plus Bortezomib/Dexamethasone Myeloma Indication in the United States

December 2nd 2021

Secura Bio decided to withdraw the approval of the new drug application for panobinostat for use in combination with bortezomib and dexamethasone to treat select patients with multiple myeloma.

Dr. Chauncey on Isatuximab Combinations in Multiple Myeloma

December 1st 2021

Thomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.

FDA Approves Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone for Relapsed/Refractory Myeloma

December 1st 2021

The FDA has approved daratumumab and hyaluronidase-fihj plus carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Dr. Rosko on Disparities Within Clinical Trials in Multiple Myeloma

November 23rd 2021

Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.

Mitigating Toxicities Will Position BCMA for Role in Triple-Class Refractory Multiple Myeloma

November 23rd 2021

In a recent OncLive Peer Exchange® program, an expert panel of oncologic hematologists discussed the latest developments and future of BCMA in multiple myeloma.

Dr. Lee on Defining Smoldering Multiple Myeloma

November 22nd 2021

Sarah S. Lee, MD, discusses definition criteria for smoldering multiple myeloma.

Dr. Shah on Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma

November 18th 2021

Mansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.

Dr. Cooper on Leveraging Novel Agents and Combos in Multiple Myeloma

November 18th 2021

Dennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.

Dr. Martin on the Utility of CAR T-Cell Therapy in Late Relapsed Multiple Myeloma

November 12th 2021

Thomas G. Martin, MD, discusses the utility of CAR T-cell therapy in late relapsed multiple myeloma.

Dr. Mikhael on the Promise of Bispecific Antibodies in Multiple Myeloma

November 12th 2021

Joseph Mikhael, MD, discusses the promise of bispecific antibodies in multiple myeloma.